Company Encyclopedia
View More
name
Citius Pharma
CTXR.US
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed.
4.514 T
CTXR.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation

    Citius Pharmaceuticals Inc. has announced the launch of LYMPHIR, a treatment for cutaneous T-cell lymphoma, marking its first marketed product by Citius Oncology. The company also highlighted other development programs, including Mino-Lok® and Halo-Lido, which have shown positive trial results. Citius Oncology, a majority-owned subsidiary, operates under a shared management agreement with Citius Pharmaceuticals to enhance operational efficiency. This update was published on December 1, 2025.

    Reuters·
    US
    CTOR
    -9.02%
    US
    CTXR
    +9.17%
    Reuters·
    US
    CTOR
    -9.02%
    US
    CTXR
    +9.17%

    Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading

    Biotech and healthcare stocks experienced significant after-hours trading activity on November 21, 2025. Butterfly Network's shares rose 6.04% due to upcoming investor events. Citius Pharma gained 7.90% following a collaboration announcement. ProQR Therapeutics and Perrigo Company saw price increases without specific news. Tempest Therapeutics reversed earlier losses after announcing an acquisition. Iterum Therapeutics and Processa Pharmaceuticals also saw price changes despite no new updates.

    rttnews·
    US
    BFLY
    +3.03%
    US
    CTXR
    +9.17%
    rttnews·
    US
    BFLY
    +3.03%
    US
    CTXR
    +9.17%

    Citius Pharmaceuticals Announces LYMPHIR Commercialization Plans

    Citius Pharmaceuticals (CTXR) announced plans to commercialize LYMPHIR, a treatment for cutaneous T-cell lymphoma, expected in Q4 2025 following FDA approval in August 2024. The U.S. market potential exceeds $400 million. Despite heavy investments in pre-commercial activities, analysts have mixed views, with a recent Buy rating and a $6.00 price target, while Spark's AI Analyst rates it as Underperform due to ongoing losses and negative cash flows. Citius focuses on innovative oncology therapies and has a market cap of $28.58M.

    Tip Ranks·
    US
    CTXR
    +9.17%
    Tip Ranks·
    US
    CTXR
    +9.17%

    Citius Pharmaceuticals Raises $6 Million in Registered Direct Offering

    Citius Pharmaceuticals Inc. has announced a registered direct offering to sell approximately 3,973,510 shares of common stock at $1.51 per share, aiming to raise about $6 million in gross proceeds. The offering includes common warrants exercisable at $1.40 per share, expiring in five years. The funds will support the commercial launch of LYMPHIR™, product development initiatives, and general corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent for this offering.

    Reuters·
    US
    CTXR
    +9.17%
    Reuters·
    US
    CTXR
    +9.17%

    Citius Pharma closes $6.0M registered direct offering under Nasdaq rules, furthers critical care product development.

    Citius Pharmaceuticals Inc. has successfully closed a $6.0 million registered direct offering under Nasdaq rules, marking a significant milestone for the company. Based in Cranford, New Jersey, Citius Pharma focuses on developing critical care products and aims to advance its innovative medical solutions with this funding. The completion of this financial transaction highlights the company's commitment to its mission of bringing pioneering medical solutions to market.

    Unusual Whales·
    US
    CTXR
    +9.17%
    Unusual Whales·
    US
    CTXR
    +9.17%
    © 2025 Longbridge｜Disclaimer